Denmark winning the Scandinavian leadership battle of Pharmaceutical development
Monday, 06 February 2012
Swedish pharmaceutical industry is waning, worker here are gradually
moving south to Denmark where the sector there is booming and had over
It had now be
contented that the Pharmaceutical sector is a sector that will bring
Denmark back to its best because of the design f the sector in Denmark
characterised by its smaller holder schemes and various forms of
funds and foundation led research.
This is not so
in Sweden where there it has the tradition to rely on big money and
sprawling establishments that makes shareholder to pressurise such
establishment with traditionally have the tendency to harbour
uncertainty. In Sweden they are forced to produce results by all means.
As Astra Zeneca
recently announced the dismissal of many workers, the Danish
pharmaceuticals such as Lundbeck are making impressive in route into
gaps being lost by the Swedish giants. As such they are attracting
Swedish medical researchers who are living on the border and crossing
to the Denmark to work daily.
the Öresund Institute, today some 700 Swedes commute to work within the
Danish biotechnology and pharmaceutical industry, which is growing fast.
Since 1998, the
two big companies, Novo Nordisk and Lundbeck, have increased their
workforce by 70 percent to over 15 000 people. Within the same period,
the two big pharmaceutical in Sweden, Astra Zeneca and Pharmacia
Upjohn, have declined by almost 20 percent to 12 000 reports radio
success has been driven according to Jan Edling, an analyst at state
innovation agency, Vinnova, by long-term and stable ownership.
There is encouragement, growth and no shareholders putting pressures on the rather smaller cap companies here.
research and development in Denmark is ahead of Sweden. In the current
situation, the Danes have 140 products in 'Phase 1 tests, compared with
about 75 in Sweden.
In Denmark, it
is believed that there is stable ownership of the pharmaceuticals
development because they are kept in funds and foundations which have
an impact on the ownerships putting limited pressures on things like
have sought other options which instead of merging with others to grow
big with the aim of gaining competitive advantage and eliminate
competitors, have perhaps made contract to share the risk when it comes
to producing a drug in the late phase. Looking at alternative solutions
instead of becoming a huge business, something Sweden always wants to
be is not a common feat in Denmark and this explains their success.
By Scancomark.se Team
Back to top